Oncology

News

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.

R&D

Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.

News

International cancer experts have called for big changes to bile duct cancer, which kills three-quarters of patients within a year of diagnosis.

News

Ipsen's Ojemda is on course to become the first targeted medicine in the EU for some children with a form of brain cancer known as low-grade glioma.